Correlation Between Microsoft and BioCryst Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Microsoft and BioCryst Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Microsoft and BioCryst Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Microsoft and BioCryst Pharmaceuticals, you can compare the effects of market volatilities on Microsoft and BioCryst Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Microsoft with a short position of BioCryst Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Microsoft and BioCryst Pharmaceuticals.

Diversification Opportunities for Microsoft and BioCryst Pharmaceuticals

0.2
  Correlation Coefficient

Modest diversification

The 3 months correlation between Microsoft and BioCryst is 0.2. Overlapping area represents the amount of risk that can be diversified away by holding Microsoft and BioCryst Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioCryst Pharmaceuticals and Microsoft is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Microsoft are associated (or correlated) with BioCryst Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioCryst Pharmaceuticals has no effect on the direction of Microsoft i.e., Microsoft and BioCryst Pharmaceuticals go up and down completely randomly.

Pair Corralation between Microsoft and BioCryst Pharmaceuticals

Given the investment horizon of 90 days Microsoft is expected to generate 0.47 times more return on investment than BioCryst Pharmaceuticals. However, Microsoft is 2.11 times less risky than BioCryst Pharmaceuticals. It trades about 0.22 of its potential returns per unit of risk. BioCryst Pharmaceuticals is currently generating about 0.03 per unit of risk. If you would invest  41,287  in Microsoft on September 22, 2024 and sell it today you would earn a total of  2,373  from holding Microsoft or generate 5.75% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Microsoft  vs.  BioCryst Pharmaceuticals

 Performance 
       Timeline  
Microsoft 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Microsoft are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable technical and fundamental indicators, Microsoft is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.
BioCryst Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days BioCryst Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, BioCryst Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Microsoft and BioCryst Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Microsoft and BioCryst Pharmaceuticals

The main advantage of trading using opposite Microsoft and BioCryst Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Microsoft position performs unexpectedly, BioCryst Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will offset losses from the drop in BioCryst Pharmaceuticals' long position.
The idea behind Microsoft and BioCryst Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Valuation
Check real value of public entities based on technical and fundamental data
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes